北京招聘

Antibody Discovery (Sr. /Pr.) Investigator

Biologics department of BeiGene is dedicated to the discovery and development of novel therapeutic monoclonal antibodies for oncology indications. We are seeking a highly motivated leader to lead antibody discovery effort to support cancer drug discovery. This is an exciting opportunity to drive the biologics therapeutics pipelines in BeiGene. In this role the scientist is expected to be familiar with antibody discovery technologies, including but not limited to antibody generation from hybridoma single B/phage display/yeast display/nanobody platform, to expedite the process and deliver high quality lead molecules.



Major responsibilities:

In charge of antibody discovery from hybridoma/yeast display/phage display/nanobody platforms. Streamline workflow of antibody discovery platforms to expedite process and deliver high quality lead molecules.

Fully integrate discovery technologies into antibody lead generation pipelines.

Be a champion in the lead discovery process and collaborate with biology project leaders closely to progress respective pipelines.

Stay informed and contribute to the vision in the technology development space especially in antibody discovery area.

Accomplish goals within project timelines
Qualifications:

Ph.D. degree in molecular/cell biology, immunology, biotechnology, antibody discovery on hybridoma single B/nanobody/phage display/yeast display platforms, and related fields.

Strong expertise at antibody generation, antibody screening, antibody characterization for developability analysis.

Experience of leading a team is required.

Excellent skills in problems solving, proficient in communication in English and English writing.

Demonstrated ability to work in a multidisciplinary biologics’ discovery team. Ability to work in collaborative environment and contribute to team projects.

Strong background of tumor biology is preferred.

百济神州是一家立足于科学的全球性生物科技公司，专注于开发创新、可负担的药物，旨在为全球患者改善治疗效果，提高药物可及性。目前公司广泛的药物组合包括40多款临床候选药物。公司通过加强自主研发能力和合作，加速推进多元、创新的药物管线开发。我们致力于在2030年前为全球20多亿人全面改善药物可及性。百济神州在全球五大洲打造了一支超过8,000人的团队。